The CLL treatment landscape has been revolutionized in recent years, with a wide range of novel treatments available including Bruton tyrosine kinase inhibitors (BTKis), anti-apoptopic protein B-cell lymphoma 2 (BCL-2) inhibitors, phosphoinositide 3-kinase (PI3K) inhibitors, and anti-CD20 monoclonal antibodies (1, 8). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.